Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01GRKP0CBQMV9DTXT5T16ASAEB> ?p ?o. }
Showing items 1 to 26 of
26
with 100 items per page.
- 01GRKP0CBQMV9DTXT5T16ASAEB classification A1.
- 01GRKP0CBQMV9DTXT5T16ASAEB date "2023".
- 01GRKP0CBQMV9DTXT5T16ASAEB language "eng".
- 01GRKP0CBQMV9DTXT5T16ASAEB type journalArticle.
- 01GRKP0CBQMV9DTXT5T16ASAEB hasPart 01GRKPC6WK336RMD3YBM98XYP0.pdf.
- 01GRKP0CBQMV9DTXT5T16ASAEB subject "Medicine and Health Sciences".
- 01GRKP0CBQMV9DTXT5T16ASAEB doi "10.3390/ijms24032894".
- 01GRKP0CBQMV9DTXT5T16ASAEB issn "1422-0067".
- 01GRKP0CBQMV9DTXT5T16ASAEB issue "3".
- 01GRKP0CBQMV9DTXT5T16ASAEB volume "24".
- 01GRKP0CBQMV9DTXT5T16ASAEB abstract "Advanced glycation end products (AGEs) are a class of compounds formed by nonenzymatic interactions between reducing sugars and proteins, lipids, or nucleic acids. AGEs can alter the protein structure and activate one of their receptors, specifically the receptor for advanced glycation end products (RAGE). These phenomena impair the functions of cells, extracellular matrix, and tissues. RAGE is expressed by a variety of cells and has been linked to chronic inflammatory autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome. The soluble (s)RAGE cleavage product is a positively charged 48-kDa cleavage product that retains the ligand binding site but loses the transmembrane and signaling domains. By acting as a decoy, this soluble receptor inhibits the pro-inflammatory processes mediated by RAGE and its ligands. In the present review, we will give an overview of the role of AGEs, sRAGE, and RAGE polymorphisms in several rheumatic diseases. AGE overproduction may play a role in the pathogenesis and is linked to accelerated atherosclerosis. Low serum sRAGE concentrations are linked to an increased cardiovascular risk profile and a poor prognosis. Some RAGE polymorphisms may be associated with increased disease susceptibility. Finally, sRAGE levels can be used to track disease progression.".
- 01GRKP0CBQMV9DTXT5T16ASAEB author 00FE98D2-F0EE-11E1-A9DE-61C894A0A6B4.
- 01GRKP0CBQMV9DTXT5T16ASAEB author 02CF2A50-F0EE-11E1-A9DE-61C894A0A6B4.
- 01GRKP0CBQMV9DTXT5T16ASAEB author 96E25A02-81D9-11E6-9883-EC8EB5D1D7B1.
- 01GRKP0CBQMV9DTXT5T16ASAEB author F41E7EB6-F0ED-11E1-A9DE-61C894A0A6B4.
- 01GRKP0CBQMV9DTXT5T16ASAEB dateCreated "2023-02-06T15:37:40Z".
- 01GRKP0CBQMV9DTXT5T16ASAEB dateModified "2024-12-12T10:19:08Z".
- 01GRKP0CBQMV9DTXT5T16ASAEB name "The potential influence of advanced glycation end products and (s)RAGE in rheumatic diseases".
- 01GRKP0CBQMV9DTXT5T16ASAEB pagination urn:uuid:abb6320f-6fa2-45cc-95e4-a11b3668bcea.
- 01GRKP0CBQMV9DTXT5T16ASAEB publisher urn:uuid:edb8accc-ff8f-4b44-a625-1213b7625e11.
- 01GRKP0CBQMV9DTXT5T16ASAEB sameAs LU-01GRKP0CBQMV9DTXT5T16ASAEB.
- 01GRKP0CBQMV9DTXT5T16ASAEB sourceOrganization urn:uuid:6bf7fc4e-e329-4ad5-835e-7d95a4f9b3c0.
- 01GRKP0CBQMV9DTXT5T16ASAEB sourceOrganization urn:uuid:97e5b9fe-bb19-425c-bcb5-87f57e5d735c.
- 01GRKP0CBQMV9DTXT5T16ASAEB sourceOrganization urn:uuid:9835d0c1-0947-44d5-88e9-698e54c47280.
- 01GRKP0CBQMV9DTXT5T16ASAEB sourceOrganization urn:uuid:f27bd440-dd3f-4cdd-b7be-2b7386d2ff68.
- 01GRKP0CBQMV9DTXT5T16ASAEB type A1.